| ID | 116083 |
| 著者 |
Kato, Yoshinobu
Kanaiso Hospital
Kato, Yoshikane
Kanaiso Hospital
Matsuzaki, Sayuri
Kanaiso Hospital
Waka, Shinnichi
Kanaiso Hospital
Ogura, Katsunori
Kanaiso Hospital
|
| キーワード | Xultophy
Degludec and Liraglutide
Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
Dual Action of Liraglutide and Insulin Degludec
European Xultophy Treatment Retrospective Audit
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.
|
| 掲載誌名 |
Asploro Journal of Biomedical and Clinical Case Reports
|
| ISSN | 25820370
|
| 出版者 | Asploro
|
| 巻 | 4
|
| 号 | 1
|
| 開始ページ | 77
|
| 終了ページ | 83
|
| 発行日 | 2021-04-06
|
| 権利情報 | This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
